Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 06 September 2013 | By Alexander Gaffney, RAC,
When it comes to legislation and regulation, word choice matters greatly. As any lawyer who specializes in constitutional law can tell you, the inclusion of a single seemingly inconsequential word can mean the difference between a policy that stands the test of time and one that is subject to endless argument.
And when it comes to a new draft policy proposed by the European Medicines Agency (EMA) that would increase clinical trials transparency in the EU, the inclusion of just one word has industry officials crying foul.
EMA has been moving toward a policy of transparency since at least November 2010, when it first announced its intent to eventually publish all research data provided to it in support of a regulatory dossier or application. The plan kicked into high gear in July 2012, when reports emerged that EMA was formally developing the plan, which it did in June 2013.
That plan has won rave reviews from some transparency advocates, including those behind the AllTrials campaign, which is campaigning for the release of all clinical data. Industry, however, has been far less supportive, with at least two-AbbVie (formerly of Abbott Laboratories) and InterMune-suing the agency to stop it from releasing what they called "commercially confidential information."
Those arguments evidently held enough weight with the General Court of the EU to merit an interim order barring the agency from publishing its transparency plan, at least for the time being.
In the meantime, EMA has been moving forward with plans to allow select access to the contested documents on a "case-by-case" basis, and has continued to debate the issue with industry.
Recently, two industry groups, US-based PhRMA and the EU-based European Federation of Pharmaceutical Industries and Associations (EFPIA), released their own data transparency plan, favoring a model that allows select access to data on a case-by-case basis. That model, they said, would balance the ability to conduct research with the need for patient privacy and the ability to protect commercial information from foreign and domestic competitors.
But with its own plans now out for public consumption, EFPIA has moved into attack mode. In comments released on 5 September 2013, the group took strong issue with EMA's choice of words in its proposal.
"I have some serious reservations about [this policy]," wrote EFPIA General Director Richard Bergström in a blog post.
"To make a very long story short, I'd like to point to a single word," Bergström continued. "In line 15 of the EMA policy, are written the words, 'There is a growing demand for full transparency from certain external stakeholders in the debate...'"
The key word there, he adds, is full, as in full transparency. This contrasts with the PhRMA/EFPIA policy, which calls for only partial transparency.
The question, then, is one of sufficiency. Is a clinical transparency policy sufficient if it is not fully transparent, or could it meet the threshold by releasing partially redacted data? Bergström calls for "responsible or appropriate transparency" to "best improve access to clinical trials data while taking into account the need to protect public health."
According to EFPIA, full transparency "carries real dangers" with respect to three factors:
"By employing terminology and conditions which are too broad, the EMA draft Policy suggests a lack of protection of commercial confidential information (CCI) that not only threatens incentives to innovate, but also comes into conflict with EU law," EFPIA wrote in an accompanying executive summary of its comments to EMA.
What remains to be seen, however, is whether EFPIA's comments will weigh on the minds of regulators. Some, including EMA's Chief Medical Officer Han-Georg Eichler, have aggressively pushed for full transparency measures, arguing that full transparency is in the best interest of patients, whom he argues the pharmaceutical industry ultimately works for.
"I hope everybody will learn that daylight is the best disinfectant and this will be a contributing step in rebuilding trust in the regulator and in the industry," Eichler told Reuters in July 2012.
Can sunlight still disinfect with clouds in the sky? Industry will have to hope EMA thinks so.
EFPIA Comments
Tags: EFPIA, Transparency, clinical trials, EU
Regulatory Focus newsletters
All the biggest regulatory news and happenings.